Skip to content
Open access

Ferumoxytol dose optimization for three-dimensional whole-heart magnetic resonance imaging in patients with congenital heart disease.

Jul 2026 · Pediatric Radiology · 1 citation · 15 references
Medicine

TL;DR

Ferumoxytol-enhanced 3D WH imaging provides diagnostic-quality assessment across 1-3 mg/kg dosing, and dose-dependent TI shortening follows a nonlinear, saturating pattern, supporting optimized low-dose protocols.

Abstract

Background

Ferumoxytol is used off-label as a contrast agent for cardiovascular magnetic resonance (CMR). However, the dose-response relationship between ferumoxytol, longitudinal relaxation, and image quality in pediatric and young patients remains unclear.

Objective

To evaluate the effects of sequential ferumoxytol dose escalation on three-dimensional (3D) whole-heart (WH) image quality and blood-pool nulling inversion time (TI), a physiologic surrogate of post-contrast T1 shortening.

Materials And Methods

In this prospective study, 45 patients with congenital heart disease underwent ferumoxytol-enhanced 3D WH CMR at 1.5 T using sequential dose regimens (1 mg/kg→2 mg/kg or 2 mg/kg→3 mg/kg). Right coronary artery (RCA) image quality and visible length, contrast-to-noise ratio (CNR), and image quality of the cardiac chambers and great vessels, as well as diagnostic completeness, were assessed. Blood-pool and myocardial nulling TI were measured using Look-Locker sequences. Baseline-adjusted change-score regression was the primary analysis, with mixed-effects ANCOVA performed to model TI behavior while accounting for repeated within-patient measurements.

Results

No significant differences were observed in CNR, RCA length, image quality, or diagnostic completeness between all doses (all P>0.05). Myocardial and blood-pool nulling TI shortened significantly with dose escalation (P≤0.02). Change in blood-pool TI after the second dose was strongly predicted by TI after the first dose (β=-0.63, P<0.001), whereas starting dose (1 mg/kg or 2 mg/kg) was not associated with TI change (P=0.70). At 1 mg/kg, prolonged myocardial nulling TI may encroach upon the systolic rest period.

Conclusions

Ferumoxytol-enhanced 3D WH imaging provides diagnostic-quality assessment across 1-3 mg/kg dosing. Dose-dependent TI shortening follows a nonlinear, saturating pattern, supporting optimized low-dose protocols.

Read PDF

Similar papers

Sep 2026

Gadopiclenol for Cardiac MRI: Comparison of Myocardial T1 Relaxation Times and Subjective Image Quality at Different Doses in Patients With Anderson-Fabry Disease.

Preliminary findings support that dose reduction to 0.05 mmol/kg gadopiclenol may be feasible in CMR, however, validation through prospective studies is needed before recommending lower-dose gadopiclenol broadly in routine CMR.

Alena T. Kollmann, H. Huflage, R. Dazeh et al. · 0 citations
Open access Aug 2026

Measurements of Liver and Bone Marrow Proton Density Fat Fraction in the Setting of Ferumoxytol-Enhanced MRI.

BACKGROUND Proton density fat fraction (PDFF) is typically measured using confounder-corrected, multi-echo, gradient-recalled-echo chemical-shift-encoded (CSE)-MRI. Ferumoxytol, an iron-based MRI contrast agent, increases liver and bone marrow (BM) R2*, a major confounder of PDFF. PURPOSE To assess the impact of feru...

L. Müller, Srijyotsna Volety, J. Grunz et al. · 1 citation
Open access Aug 2026

Whole heart non-contrast 4D Flow MRI at 3.0T for clinical follow-up of congenital heart disease in children and adolescents.

Accelerated WH-4DF MRI is clinically robust and broadly applicable across CHD, including complex postoperative anatomies, and provides comparable numbers to 2D-PC, reproducible, and time-efficient flow quantification with superior coverage and reduced operator dependence.

J. van Schuppen, A. E. van der Hulst, R. Takx et al. · 0 citations
Open access Aug 2026

4D flow cardiac magnetic resonance postprocessing in congenital heart disease: SCMR FLIICR workgroup recommendations.

This document addresses the needs for an "ideal" post-processing software for 4D flow in patients with CHD and provides information on general requirements, velocity encoding, offset and aliasing correction, visualization, segmentation and reconstruction as well as output data.

Julio Garcia, J. Geiger, Adam B. Christopher et al. · 0 citations
Open access Aug 2026

A contrast-enhanced CMR-based risk score integrating microvascular obstruction and intramyocardial hemorrhage extent for prognostic evaluation

This study aims to compare the prognostic value of the extent of microvascular obstruction (MVO) combined with intramyocardial hemorrhage (IMH) for major adverse cardiovascular events (MACE) in patients with STEMI. We analyzed 568 STEMI patients in this retrospective multicenter study. Microvascular injury was visualiz...

Xing-Yu Gu, Ting-Xuan Yin, Ling-Yi Yu et al. · 0 citations
Open access Aug 2026

Enhancing risk prediction for sudden cardiac death: quantitative late gadolinium enhancement analysis in hypertrophic cardiomyopathy

Both single- and dual-threshold LGE quantification independently predict SCD in patients with HCM, while dual-threshold gray zone metrics demonstrate stronger prognostic associations, underscore the importance of standardizing LGE quantification to improve SCD risk stratification in patients with HCM.

Li-Li Wang, Hongbo Zhang, Guan-Yu Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.